Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Core Insights - Corbus Pharmaceuticals is focused on developing new therapies in oncology and obesity, with promising data for CRB-701 and CRB-913 expected to drive significant developments in 2026 [2][11]. Corporate and Program Updates - CRB-701 is a next-generation antibody-drug conjugate targeting Nectin-4, with Fast Track designations from the FDA for treating head and neck squamous cell carcinoma (HNSCC) and cervical cancer [3]. - CRB-913 is an oral CB1 inverse agonist aimed at obesity treatment, showing rapid weight loss and favorable gastrointestinal tolerability [4]. - Data presented at ESMO 2025 indicated an unconfirmed objective response rate for CRB-701 of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer, with no severe treatment-related adverse events reported [5][6]. Financial Results - For Q4 2025, the company reported a net loss of approximately $20.6 million, compared to a net loss of $9.5 million in Q4 2024, reflecting an increase in operating expenses primarily due to clinical development [8][9]. - Operating expenses rose to approximately $22.0 million in Q4 2025 from $12.6 million in Q4 2024 [9]. - The company had $163.3 million in cash and equivalents as of December 31, 2025, following a public offering that raised $75 million, which is expected to fund operations into 2028 [10].